Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity

REFERENCES

• Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol 1988;106:471–479
   PubMedGoogle Scholar
• Palmer EA, Hardy RJ, Dobson V, et al. Cryotherapy for Retinopathy of Prematurity Cooperative Group. 15-Year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 2005;123:311–318
   PubMed Web of Science ®Google Scholar
• Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684–16894
   PubMed Web of Science ®Google Scholar
• Ells AL, Holmes JM, Astle WF, et al. Telemedicine approach to screening for severe retinopathy of prematurity: a pilot study. Ophthalmology 2003;110:2113–2117
   PubMed Web of Science ®Google Scholar
• Photographic Screening for Retinopathy of Prematurity Study (PHOTO-ROP) Cooperative Group. The photographic screening for retinopathy of prematurity study (photo-ROP). Primary outcomes. Retina 2008;28:S47–S54
   PubMed Web of Science ®Google Scholar
• McNamara JA, Tasman W, Vander JF, Brown GC. Diode laser photocoagulation for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1992;110:1714–1716
   PubMedGoogle Scholar
• Capone A Jr, Diaz-Rohena R, Sternberg P Jr, et al. Diode-laser photocoagulation for zone 1 threshold retinopathy of prematurity. Am J Ophthalmol 1993;116:444–450
   PubMed Web of Science ®Google Scholar
• Hunter DG, Repka MX. Diode laser photocoagulation for threshold retinopathy of prematurity. A randomized study. Ophthalmology 1993;100:238–244
   PubMed Web of Science ®Google Scholar
• Banach MJ, Ferrone PJ, Trese MT. A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology 2000;107:324–328
   PubMed Web of Science ®Google Scholar
• Prenner JL, Capone A Jr, Trese MT. Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology 2004;111:2271–2273
   PubMed Web of Science ®Google Scholar
• Capone A Jr, Trese MT. Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments. Ophthalmology 2001;108:2068–2070
   PubMed Web of Science ®Google Scholar
• Hubbard GB III, Cherwick DH, Burian G. Lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Ophthalmology 2004;111:2274–2277
   PubMed Web of Science ®Google Scholar
• Kychenthal A, Dorta P. 25-Gauge lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Retina 2008;28:S65–S68
   PubMed Web of Science ®Google Scholar
• Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005;123:991–1915
   PubMedGoogle Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611
   PubMed Web of Science ®Google Scholar
• Bossi E, Koerner F. Retinopathy of prematurity. Intens Care Med 1995;21:241–246
   PubMed Web of Science ®Google Scholar
• Berkowitz BA, Penn JS. Abnormal panretinal response pattern to carbogen inhalation in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 1998;39:840–845
   PubMed Web of Science ®Google Scholar
• Gu X, El-Remessy AB, Brooks SE, et al. Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite. Am J Physiol Cell Physiol 2003;285:C546–C554
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024–1028
   PubMed Web of Science ®Google Scholar
• Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219–1228
   PubMedGoogle Scholar
• Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division: evidence that ‘physiological hypoxia’ is the stimulus for normal retinal development. Invest Ophthalmol Vis Sci 1995;36:1201–12014
   PubMed Web of Science ®Google Scholar
• Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133–140
   PubMedGoogle Scholar
• Stevens TP, Finer NN, Carlo WA, Szilagyi PG, et al. Respiratory outcomes of the Surfactant Positive Pressure and Oximetry Randomized Trial (SUPPORT). J Pediatr 2014;165:240.e4–249.e4
   PubMed Web of Science ®Google Scholar
• Khadawardi E, Al Hazzani F. Oxygen saturation and outcomes in preterm infants, The BOOST II United Kingdom, Australia, and New Zealand Collaborative Groups. J Clin Neonatol 2013;2:73–75
   PubMedGoogle Scholar
• Askie LM, Brocklehurst P, Darlow BA, et al. NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. BMC Pediatr 2011;11:6
   PubMed Web of Science ®Google Scholar
• Leone TA, Rich W, Finer NN. A survey of delivery room resuscitation practices in the United States. Pediatrics 2006; 117:e164–e175
   PubMed Web of Science ®Google Scholar
• Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15:4738–4747
   PubMed Web of Science ®Google Scholar
• Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1:182–193
   PubMed Web of Science ®Google Scholar
• Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538–1544
   PubMed Web of Science ®Google Scholar
• Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009;116:1599–1603
   PubMed Web of Science ®Google Scholar
• Hartnett ME. Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2010;108:96–119
   PubMedGoogle Scholar
• FDA approves new drug treatment for age-related macular degeneration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108385.htm
   Google Scholar
• Autrata R, Krejcirova I, Senkova K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 2012;22:687–694
   PubMed Web of Science ®Google Scholar
• Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol 2012;22(5):685–686
   PubMed Web of Science ®Google Scholar
• Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol 2015;15:20
   PubMed Web of Science ®Google Scholar
• Mota Á, Carneiro Â, Breda J, et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol 2012;3:136–141
   PubMedGoogle Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 2008;92(5):667–668
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–615
   PubMed Web of Science ®Google Scholar
• Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 2015;122:1008–1015
   PubMed Web of Science ®Google Scholar
• Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013;155:1119.e1–1124.e1
   PubMed Web of Science ®Google Scholar
• Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 2014;121:2212–2219
   PubMed Web of Science ®Google Scholar
• Tahija SG, Hersetyati R, Lam GC, et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 2014;98:507–512
   PubMed Web of Science ®Google Scholar
• Castellanos MA, Schwartz S, García-Aguirre G, Quiroz-Mercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 2013;97:816–819
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859–870
   PubMed Web of Science ®Google Scholar
• Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814–2823
   PubMed Web of Science ®Google Scholar
• Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002;9:152–166
   PubMedGoogle Scholar
• Ehlers N, Mathiesen ME, Andersen H. The prenatal growth of the human eye. Acta Ophthalmol (Copenh) 1968;46:329–349
   PubMed Web of Science ®Google Scholar
• Larsen JS. The sagittal growth of the eye. Acta Ophthalmol 1971;49:441–444
   PubMed Web of Science ®Google Scholar
• Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol 2014;92:577–581
   PubMed Web of Science ®Google Scholar
• Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 2011;31:161–168
   PubMed Web of Science ®Google Scholar
• Chuang LH, Wu WC, Yeung L, et al. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion. Ophthalmic Res 2011;45:31–35
   PubMed Web of Science ®Google Scholar
• Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707–716
   PubMed Web of Science ®Google Scholar
• Hislop AA, Wigglesworth JS, Desai R. Alveolar development in the human fetus and infant. Early Hum Dev 1986;13:1–11
   PubMed Web of Science ®Google Scholar
• Thebaud B. Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology 2007;91:291–297
   PubMed Web of Science ®Google Scholar
• Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002;8:702–710
   PubMed Web of Science ®Google Scholar
• Sentilhes L, Marret S, Leroux P, et al. Vascular endothelial growth factor and its high-affinity receptor (VEGFR-2) are highly expressed in the human forebrain and cerebellum during development. J Neuropathol Exp Neurol 2010;69:111–128
   PubMed Web of Science ®Google Scholar
• Spandau U. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Acta Ophthalmol 2013;91:e154
   PubMed Web of Science ®Google Scholar
• Hård A-L, Smith LE, Hellström A. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal Neonatal Med 2013:S1744-165X(13)00007-3
   Google Scholar
• Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390–1395
   PubMed Web of Science ®Google Scholar
• Hellström A, Engström E, Hård AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003;112:1016–1020
   PubMed Web of Science ®Google Scholar
• Ley D1, Hansen-Pupp I, Niklasson A, et al. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res 2013;73:68–74
   PubMed Web of Science ®Google Scholar
• Nakano M, Satoh K, Fukumoto Y, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007;100:662–669
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014;4:CD004863
   PubMedGoogle Scholar
• Pieh C, Agostini H, Buschbeck C, et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 2008;92:689–6893
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wang H, Culp D, et al. Targeting Müller Cell–Derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2014;55:824–831
   PubMed Web of Science ®Google Scholar